Multiple lymphatic-venous anastomoses in reducing the risk of lymphedema in melanoma patients undergoing complete lymph node dissection. A retrospective case-control study

Eleonora Nacchieroa, Michele Marucciaa, Michelangelo Vestita, Rossella Elia , Paolo Marannino, Giuseppe Giudicea. Journal of Plastic, Reconstructive & Aesthetic Surgery (2019) 000, 1–7

Click to read the abstract

Multiple lymphatic-venous anastomoses in reducing the risk of lymphedema in melanoma patients undergoing complete lymph node dissection. A retrospective case-control study

Eleonora Nacchieroa, Michele Marucciaa, Michelangelo Vestita, Rossella Elia , Paolo Marannino, Giuseppe Giudicea. Journal of Plastic, Reconstructive & Aesthetic Surgery (2019) 000, 1–7

Summary Background: Sentinel lymph node biopsy (SLNB) is an indispensable surgical procedure in staging and management of intermediate-to-thick melanomas. Although recent studies have demonstrated that complete lymph node dissection (CLND) does not improve 3-year specific survival, its utility in increasing the disease-free period and the control of local disease remains confirmed. The most frequent complication related to CLND is lymphedema, which may affect up to 20% of patients undergoing CLND. The preventive use of lymphatic-venous micro-anastomoses could avoid this complication.

Materials and methods: We performed a single-institution retrospective case-control study. CLND was proposed to all subjects with positive-SLNB; a preventive procedure involving multiple lymphaticovenular anastomoses (PMA) was performed in a cohort of subjects undergoing CLND. Frequency of lymphedema was compared among subjects undergoing and not-undergoing PMA during CLND.

Results: We selected patients affected by melanoma of the trunk and with a minimum follow- up of 3 years, identifying 23 patients who underwent PMA during CLND (PMA group) and 120 subjects who underwent CLND without PMA (control group). The frequency of lymphedema was significantly lower in the PMA group than in the control group (4.3% vs. 24.2%, p = 0.03). Patients of the PMA group and the control group showed similar 3-year recurrence-free period (65.2% vs. 62.5%, log-rank test p = 0.88) and 3-year overall survival (73.9% vs. 72.5%, log-rank test p = 0.97) and frequency of non sentinel-node metastases (26.7% vs. 30.4%, p = 0.71).

Conclusion: PMA appear to represent a useful and safe procedure in reducing the risk of lymphedema in patients with melanoma undergoing CLND.

Main findings

  • All patients underwent a clinical and imaging follow- up (chest X-ray, abdominal and lymphatic ultrasound, and SPECT/CT for difficult areas) every 6 months for the first 5 years and yearly thereafter. During these follow-up visits, calf and/or biceps circumference was measured and water volumetry was performed to detect lymphedema, 22 defined as an increase in the sum of circumferences of the defined points along the limb > = 7% and/or a whole limb volume percentage change of > = 15%.
  • During a follow-up period of 3 years, patients were evaluated at 6 months, then 12 months, and then once a year. Lymphedema was detected in 29 of 120 (24.2%) subjects in the control group and 1 of 23 (4.3%) patients in the PMA group.
  • Lymphedema was significantly more common in the control group than in the PMA group.